Cantor Fitzgerald set a $61.00 price target on Global Blood Therapeutics (NASDAQ:GBT) in a research report sent to investors on Monday. The firm currently has a buy rating on the stock.

“At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients.”,” Cantor Fitzgerald’s analyst wrote.

GBT has been the topic of a number of other research reports. Oppenheimer set a $53.00 target price on shares of Global Blood Therapeutics and gave the company a buy rating in a research report on Monday, October 30th. J P Morgan Chase & Co reiterated a buy rating on shares of Global Blood Therapeutics in a research report on Monday, October 23rd. BidaskClub downgraded shares of Global Blood Therapeutics from a hold rating to a sell rating in a research report on Thursday, September 14th. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a hold rating to a buy rating and set a $36.00 target price on the stock in a research report on Tuesday, October 10th. Finally, Needham & Company LLC assumed coverage on shares of Global Blood Therapeutics in a research report on Wednesday, September 20th. They set a buy rating and a $51.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Global Blood Therapeutics has an average rating of Buy and an average price target of $60.71.

Global Blood Therapeutics (GBT) traded down $0.93 during trading on Monday, hitting $44.77. 4,094,500 shares of the company were exchanged, compared to its average volume of 1,003,992. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the business posted ($0.58) EPS. research analysts expect that Global Blood Therapeutics will post -2.55 earnings per share for the current fiscal year.

In other news, Director Charles J. Homcy sold 70,000 shares of the company’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares in the company, valued at approximately $2,830,652.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Peter Radovich sold 12,500 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $35.00, for a total transaction of $437,500.00. Following the completion of the sale, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The disclosure for this sale can be found here. Insiders have sold a total of 88,500 shares of company stock valued at $3,003,350 in the last 90 days. 5.30% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC grew its stake in shares of Global Blood Therapeutics by 0.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,943 shares of the company’s stock worth $846,000 after acquiring an additional 284 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Global Blood Therapeutics by 10.1% in the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after acquiring an additional 440 shares in the last quarter. Fiduciary Trust Co. grew its stake in shares of Global Blood Therapeutics by 7.8% in the 3rd quarter. Fiduciary Trust Co. now owns 23,580 shares of the company’s stock worth $732,000 after acquiring an additional 1,701 shares in the last quarter. American International Group Inc. grew its stake in shares of Global Blood Therapeutics by 8.1% in the 3rd quarter. American International Group Inc. now owns 24,752 shares of the company’s stock worth $769,000 after acquiring an additional 1,850 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in shares of Global Blood Therapeutics by 7.9% in the 2nd quarter. Alps Advisors Inc. now owns 39,366 shares of the company’s stock worth $1,077,000 after acquiring an additional 2,874 shares in the last quarter. Hedge funds and other institutional investors own 90.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics (GBT) Given a $61.00 Price Target at Cantor Fitzgerald” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/12/global-blood-therapeutics-gbt-given-a-61-00-price-target-at-cantor-fitzgerald.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.